Alkem Laboratories is currently trading at Rs. 3193.20, up by 15.85 points or 0.50% from its previous closing of Rs. 3177.35 on the BSE.
The scrip opened at Rs. 3199.95 and has touched a high and low of Rs. 3225.65 and Rs. 3174.05 respectively. So far 799 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3784.00 on 11-Jan-2022 and a 52 week low of Rs. 2835.00 on 16-May-2022.
Last one week high and low of the scrip stood at Rs. 3258.15 and Rs. 3164.95 respectively. The current market cap of the company is Rs. 38260.80 crore.
The promoters holding in the company stood at 57.16%, while Institutions and Non-Institutions held 20.19% and 22.65% respectively.
The US Food and Drug Administration (USFDA) has issued three observations after inspecting Alkem Laboratories’ St Louis-based manufacturing facility. The USFDA had conducted a pre-approval inspection at the plant from October 31, 2022 to November 9, 2022. At the end of the inspection, the company received Form 483 with three observations.
There is no data integrity observation. This pre-Approval Inspection is part of the routine business operations and the company shall submit to USFDA within the stipulated timeline, a detailed response to close out the said observations.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1340.80 |
Cipla | 1476.45 |
Lupin | 2160.20 |
Zydus Lifesciences | 972.95 |
View more.. |